Withdrawal From Controlled Carbamazepine Therapy Followed by Further Carbamazepine Treatment in Patients With Dementia

Abstract

The washout data provided independent confirmation of efficacy found in the prior placebo-controlled phase of this trial. Ongoing treatment was not associated with unexpected toxicity and was associated with improvement in measures of agitation and aggression that appeared to continue for up to 12 weeks. These findings confirm and extend results from earlier placebo-controlled studies.